Prices via Intrinio. Supplier and customer ties are extracted from SEC filings and carry the sentence they came from. Not investment advice.
Prices via Intrinio. Supplier and customer ties are extracted from SEC filings and carry the sentence they came from. Not investment advice.
Amneal Pharmaceuticals, Inc.
Price, suppliers and customers from SEC filings, institutional ownership and the next report.
Nasdaq · Pharmaceutical Preparations
Prev close 16.64 · gapped above the open, then crossed back over prior close. High/low 17.88 at 5:45 am ET, 16.61 at 3:30 pm ET.
Sources
sec edgar · verbatim disclosureEach tie, with the sentence that disclosed it. Open a row for the wording and the filing it came from.
“The following table summarizes the percentages of net revenues from each of the Company's customers that individually accounted for 10% or more of its net revenues: For the year ended December 31, 2025 2024 2023 Customer A 25 % 23 % 24 %”
$755M relationship
basisAMRX fy2025 · closed 2025-12 $3.0B
FILING10-K0001723128-26-000011cik 0001723128
“Pursuant to a development and supply agreement with Kashiv Biosciences LLC ("Kashiv") for a long-acting injectable, we paid Kashiv $10.0 million in February 2025 for the achievement of a regulatory milestone, which was accrued as of December 31, 2024.”
FILING10-K0001723128-25-000012cik 0001723128
“Our 2025 estimate includes capital expenditures for our collaboration and supply agreement with Metsera, of which we expect Metsera to reimburse us approximately $20.0 million.”
FILING10-K0001723128-25-000012cik 0001723128
“The year-over-year decrease in net operating cash flows for the year ended December 31, 2024 as compared to the prior year period was primarily driven by (i) lower collections of outstanding accounts receivable due to timing of sales in the quarter ended December 31, 2022, which benefited the year ended December 31, 2023 and (ii) receipt of a $21.4 million upfront payment associated with the license agreement with Orion Corporation during the year ended December 31, 2023, partially offset by (i) increased profitability adjusted for non-cash items, (ii) lower period over period payments associated with the Opana ER ® antitrust litigation settlement and (iii) favorable working capital movements, most notably an increase in days payables outstanding.”
FILING10-K0001723128-25-000012cik 0001723128
“Our AvKARE segment provides pharmaceuticals, medical and surgical products and services primarily to governmental agencies, predominantly focused on the U.S. Department of Defense and the U.S. Department of Veterans Affairs.”
FILING10-K0001723128-25-000012cik 0001723128
“Our AvKARE segment provides pharmaceuticals, medical and surgical products and services primarily to governmental agencies, predominantly focused on the U.S. Department of Defense and the U.S. Department of Veterans Affairs.”
FILING10-K0001723128-25-000012cik 0001723128
“Under the ApiJect Agreement, we will install and operate manufacturing equipment leased from Apiject at our Brookhaven, New York facility.”
FILING10-K0001723128-26-000011cik 0001723128
“ONGENTYS ® is an add-on treatment to carbidopa/levodopa in patients with Parkinson's disease experiencing "Off" episodes, which we commenced selling in early 2024 under a license agreement with BIAL-Portela & Ca., S.A.”
FILING10-K0001723128-25-000012cik 0001723128
“UNITHROID ® , indicated for the treatment of hypothyroidism, is sold under a license and distribution agreement with Jerome Stevens Pharmaceuticals, Inc.”
FILING10-K0001723128-25-000012cik 0001723128
“On December 30, 2021, we entered into an asset purchase agreement with certain entities affiliated with Saol International Limited (collectively, "Saol"), a private specialty pharmaceutical company, pursuant to which we agreed to acquire Saol's baclofen franchise, including Lioresal ® , LYVISPAH ™ , and a pipeline product under development (the "Saol Acquisition").”
FILING10-K0001723128-25-000012cik 0001723128
“Contingent upon Kashiv obtaining regulatory approval outside the U.S., we shall manufacture the commercial supply for Kashiv at a stated price.”
FILING10-K0001723128-25-000012cik 0001723128
“Upon achieving regulatory approval for products, Amneal will be responsible for manufacturing and supplying products to Knight.”
FILING10-K0001723128-25-000012cik 0001723128
“Upon achieving regulatory approval for products, we will be responsible for manufacturing and supplying products to Zambon.”
FILING10-K0001723128-25-000012cik 0001723128
“Pursuant to a licensing and supply agreement with mAbxience S.L. ("mAbxience") for two denosumab biosimilars referencing Prolia ® and XGEVA ® , the Company paid mAbxience $7.5 million in February 2026 upon the achievement of regulatory milestones.”
FILING10-K0001723128-26-000011cik 0001723128
“UNITHROID ® , indicated for the treatment of hypothyroidism, is sold under a license and distribution agreement with Jerome Stevens Pharmaceuticals, Inc.”
FILING10-K0001723128-25-000012cik 0001723128
“On May 8, 2025, the Company entered into a 15-year strategic collaboration agreement with ApiJect Systems, Corp. and related entities ("ApiJect"), a medical technology company focused on advanced drug delivery ("ApiJect Agreement").”
FILING10-K0001723128-26-000011cik 0001723128
“On December 19, 2025, the Company also entered into a distribution agreement with Valorum Oncology, LLC ("Valorum"), pursuant to which Valorum was appointed as Amneal's exclusive distributor of ALYMSYS ® in the territory (primarily the United States and Puerto Rico).”
FILING10-K0001723128-26-000011cik 0001723128
Watchlist prices, news filtered to it, and its next report on your desk.
Amneal Pharmaceuticals, Inc. has 6 disclosed suppliers and 11 disclosed customers. Each one is named in an SEC filing, either Amneal Pharmaceuticals, Inc.’s own annual report or the counterparty’s, and carries the sentence that discloses it.
AMRX (Amneal Pharmaceuticals, Inc.) has 6 disclosed suppliers and 11 disclosed customers, strongest disclosure first.
Suppliers:
Customers:
Select a tie for the filing sentence that discloses it; select again to open the company. Lines are disclosed suppliers and customers, coloured by industry; the closer to the centre, the more the filings disclose. A dot is green or red by today’s move. Extended: satellites hang off single companies, not bundled sectors.